Catumaxomab - Wikipedia
Catumaxomab, [1] sold under the brand name Removab among others, is a rat - mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).
Review of catumaxomab in the treatment of malignant ascites
Catumaxomab (anti-EpCAM × anti-CD3) is a hybrid, hybridoma-derived, trifunctional, monoclonal bispecific antibody, combining two half-antibodies of mouse IgG2a and rat IgG2b that represent homologous immunoglobulin subclasses.
Catumaxomab: Uses, Interactions, Mechanism of Action
2008年3月19日 · Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites 3.
Catumaxomab: clinical development and future directions
Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites. In addition, catumaxomab is a potential therapeutic option for several primary tumors since the EpCAM molecule is …
Removab® (catumaxomab) is a trifunctional antibody (trAb) that is indicated the intraperitoneal (i.p.) treatment of malignant ascites in patients EpCAM-positive carcinomas where standard therapy is not available or longer feasible.
Catumaxomab - an overview | ScienceDirect Topics
Catumaxomab is a trifunctional antibody (trAb) characterized by its unique ability to bind three different cell types: tumor cells, T-cells, and accessory cells. It has two different antigen-binding specificities: one for epithelial cell adhesion molecule (EpCAM) on tumor cells and one for the CD3 antigen on T-cells.
Novel Monoclonal Antibodies for Cancer Treatment: The …
The trifunctional antibody (trAb) catumaxomab is characterized by a unique ability to bind three different cell types: tumor cells; T-cells; and accessory cells. It binds to epithelial cell adhesion molecule (EpCAM) on tumor cells, the CD3 antigen ...
The trifunctional antibody catumaxomab for the treatment of …
The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers.
Definition of catumaxomab - NCI Drug Dictionary - NCI
A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells.
Development and approval of the trifunctional antibody catumaxomab ...
2010年10月1日 · Catumaxomab (Removab®, Fresenius Biotech GmbH, Munich, Germany) is a trifunctional antibody (trAb) characterized by its unique ability to bind three different cell types: tumor cells, T-cells, and accessory cells.
- 某些结果已被删除